


## CLAIMS

1. A method for the treatment or prophylaxis of a condition selected from a NFκB related or associated condition, a PKCβ related or associated condition, vascular or immunological conditions such as diabetes, inflammation, neurological conditions, cardiovascular disease and pain in a subject, said method comprising administering to said subject an effective amount of a compound having the structure of Formula (I):



wherein

R<sub>1</sub> is a saturated or unsaturated hydrocarbon chain of from about 9 to about 26 carbon atoms and which is optionally carries one or more of a oxa, thia, hydroxy, hydroperoxy, epoxy and peroxy substitution;

R<sub>2</sub>, R<sub>4</sub> and R<sub>6</sub> may be the same and each is selected from O<sub>2</sub>, NO, NO<sub>2</sub>, S(O)<sub>x</sub>,

C(H)<sub>y</sub>, H, COOH, P(X)<sub>δ</sub>(Y), N(H)<sub>z</sub>, C=O, OH,  $\text{---}\overset{\text{O}}{\parallel}\text{C}\text{---NH}\text{---}$ , C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amino, mono-acid di-C<sub>1-6</sub> alkylamino, C<sub>1-6</sub> alkylthio, S(O)<sub>x</sub>-C<sub>1-3</sub> alkyl, C<sub>1-6</sub> alkoxycarbonyl, halo selected from fluoro, chloro, bromo and iodo, oxo, amidino and guanidino, C<sub>2-12</sub> alkenyl, C<sub>2-12</sub> alkynyl, aryl, heteroaryl and cyano, wherein x and z are 0, 1 or 2 and y is 0, 1, 2 or 3 and X is O, S or NR<sub>8</sub>, Y is OR<sub>9</sub>, SR<sub>10</sub> or NR<sub>11</sub>R<sub>12</sub> and R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are selected from H, alkyl, alkenyl, alkynyl, aryl and heteroaryl, δ is 0 or 1;

- 138 -

each of  $R_3$ ,  $R_5$  and  $R_7$  is respectively  $[(CH_2)_j (COOH)_k]_l$ ,  $[(CH_2)_m (COOH)_n]_o$  and  $[(CH_2)_p (COOH)_q]_r$ , wherein each of  $j$ ,  $m$  and  $p$  is 0, 1, 2, 3, 4, 5 or 6, each of  $k$ ,  $n$  and  $q$  is 0, 1 or 2, and each of  $l$ ,  $o$  and  $r$  is 0 or 1,

each of  $c$ ,  $i$  and  $f$  is 0 or 1 or 2;

each of  $a$ ,  $d$  and  $g$  is 0 or 1 or 2;

each of  $b$ ,  $e$  and  $h$  is 0 or 1 or 2;

said administration being for a time and under conditions sufficient to prevent the condition or to ameliorate one or more symptoms of the condition.

2. The method of Claim 1 wherein the subject is a mammal.
3. The method of Claim 2 wherein the mammal is a human.
4. The method of Claim 1 wherein in Formula (I) each of  $i$ ,  $c$  and  $f$  is 0 (zero), two of  $i$ ,  $c$  and  $f$  is 0 (zero) or one of  $i$ ,  $c$  and  $f$  is 0 (zero); or each of  $i$ ,  $c$  and  $f$  is 1; two of  $i$ ,  $c$  and  $f$  is 1 or one of  $i$ ,  $c$  and  $f$  is 1; or each of  $i$ ,  $c$  and  $f$  is two, two of  $i$ ,  $c$  and  $f$  is two, or one of  $i$ ,  $c$  and  $f$  is two.
5. The method of Claim 1 or 4 wherein in Formula (I) each of  $g$ ,  $a$  and  $d$  is 0 (zero), two of  $g$ ,  $a$  and  $d$  is 0 (zero) or one of  $g$ ,  $a$  and  $d$  is 0 (zero); or each of  $g$ ,  $a$  and  $d$  is 1; two of  $g$ ,  $a$  and  $d$  is 1 or one of  $g$ ,  $a$  and  $d$  is 1; or each of  $g$ ,  $a$  and  $d$  is two, two of  $g$ ,  $a$  and  $d$  is two, or one of  $g$ ,  $a$  and  $d$  is two.
6. The method of Claim 1 or 4 or 5 wherein in Formula (I) each of  $h$ ,  $b$  and  $e$  is 0 (zero), two of  $h$ ,  $b$  and  $e$  is 0 (zero) or one of  $h$ ,  $b$  and  $e$  is 0 (zero); or each of  $h$ ,  $b$  and  $e$  is 1; two of  $h$ ,  $b$  and  $e$  is 1 or one of  $h$ ,  $b$  and  $e$  is 1; or each of  $h$ ,  $b$  and  $e$  is two, two of  $h$ ,  $b$  and  $e$  is two, or one of  $h$ ,  $b$  and  $e$  is two.

7. The method of Claim 1 or 4 or 5 or 6 wherein the L-amino acid is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.

8. The method of Claim 1 or 4 or 5 or 6 wherein a chemical analog of an amino acid is selected from  $\alpha$ -aminobutyric acid,  $\alpha$ -amino- $\alpha$ -methylbutyrate, aminocyclopropane-, carboxylate, aminoisobutyric acid, aminonorbornyl-, carboxylate, cyclohexylalanine, cyclopentylalanine, D-alanine, D-arginine, D-aspartic acid, methylmethionine, D-cysteine, N-methylnorleucine, D-glutamine, D-glutamic acid, methylornithine, D-histidine, N-methylphenylalanine, D-isoleucine, D-leucine, D-lysine, D-methionine, D-ornithine, D-phenylalanine, D-proline, D-serine, D-threonine, D-tryptophan, D-tyrosine, D-valine, D- $\alpha$ -methylalanine, D- $\alpha$ -methylarginine, D- $\alpha$ -methylassparagine, D- $\alpha$ -methylasspartate, D- $\alpha$ -methylcysteine, D- $\alpha$ -methylglutamine, D- $\alpha$ -methylhistidine, D- $\alpha$ -methylisoleucine, D- $\alpha$ -methylleucine, D- $\alpha$ -methyllysine, D- $\alpha$ -methylmethionine, D- $\alpha$ -methylornithine, D- $\alpha$ -methylphenylalanine, D- $\alpha$ -methylproline, D- $\alpha$ -methylserine, D- $\alpha$ -methylthreonine, D- $\alpha$ -methyltryptophan, D- $\alpha$ -methyltyrosine, D- $\alpha$ -methylvaline, D-N-methylalanine, D-N-methylarginine, D-N-methylassparagine, D-N-methylasspartate, D-N-methylcysteine, D-N-methylglutamine, D-N-methylglutamate, D-N-methylhistidine, D-N-methylisoleucine, D-N-methylleucine, D-N-methyllysine, N-methylcyclohexylalanine, D-N-methylornithine, N-methylglycine, N-methylaminoisobutyrate, N-(1-methylpropyl)glycine, N-(2-methylpropyl)glycine, D-N-methyltryptophan, D-N-methyltyrosine, D-N-methylvaline,  $\gamma$ -aminobutyric acid, L-t-butylglycine, L-ethylglycine, L-homophenylalanine, L- $\alpha$ -methylarginine, L- $\alpha$ -methylasspartate, L- $\alpha$ -methylcysteine, L- $\alpha$ -methylglutamine, L- $\alpha$ -methylhistidine, L- $\alpha$ -methylisoleucine, L- $\alpha$ -methylleucine, L- $\alpha$ -methylmethionine, L- $\alpha$ -methylnorvaline, L- $\alpha$ -methylphenylalanine, L- $\alpha$ -methylserine, L- $\alpha$ -methyltryptophan, L- $\alpha$ -methylvaline, N-(N-(2,2-diphenylethyl)carbamylmethyl)glycine and 1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane.

9. The method of Claim 1 or 4 or 5 or 6 wherein the cytokine is selected from BDNF, CNTF, EGF, EPO, FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10,

- 140 -

FGF11, FGF12, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23, G-CSF, GM-CSF, IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12, IL13, IL14, IL15, LIF, MCP1, MCP2, MCP3, MCP4, MCP5, M-CSF, MIP1, MIP2, NGF, NT 3, NT4, NT5, NT6, NT7, OSM, PBP, PBSF, PDGF, PF4, RANTES, SCF, TGF $\alpha$ , TGF $\beta$ , TNF $\alpha$ , TNF $\beta$ , TPO, VEGF, GH and insulin.

10. The method of Claim 1 or 4 or 5 or 6 wherein the apoptotic proteins is selected from A1, A9, A20, A46R, A52R, A53, A238L, Aac11, AATF, AATYK, ABIN1, ABIN-1, ABIN2, acidic sphingomyelinase, Acinus, Act1, Act2, activin, AD3LP, AD5, ADAR, adrenomedullin, aggrecan, AMAM17, 33, AI1, AIF, AILIM, AIM2, AIR, AITR, Akt, ALCAM, ALG2, ALG3, ALG4, ALP, Alix, Armadillo, AMAC1, AMH, AMID, Amida, angiotensinogen, Ankyrin, ANT1, AO7, AP1, Apaf-1, APC, APC2, APCL, APE1820, APJ, APO-1, APO-2, APO-3, Apopain, APP1, APP2, Apr, APRIL, ARA54, ARC, ARF, arkadia, ARIH1, 2, ASC, Ash2, Ask1, Ask2, ASPP1, ASPP2, AT2R1, AT2R2, ATAR, ATF1, ATF2, ATF3, ATF4, ATM, atona, ATR1, AUF1, Aven, AVP, AvrA, AvrBsT, Axam, Axin, Axin 2, Axi, b-catenin, b-TrCP, B28R, B7-1, B7-2, B7h2, B7RP1, Bach2, Bad, BAFF, BAG -1,-2, -3, -4, -5, Bak, BALF1, Bam32, BAP-1, BAP31, BAP29, BAR, BARD1, BAT3, Bax, BBc3, BCA1, BCAN, Bcl-2, BCL2, Bcl-3, Bcl-10, BCL10, Bcl-G, Bcl-Rambo, Bcl-w, Bcl-x, beclin, BEHAB, BERP, Bfl-1, BFL1, BG1, BG2, BG4, BG5, BHP1, BHRF1, BI-1, Bid, Bif-1, Bik, Bis, Bim, Bimp-1, Bimp1, Bimp2, Bimp3, BIR1, BIRP, BL-CAM, BLC, Blk, BLNK, BLR1, BLyS, BMI-1, BmP109, BNIP3, BNIP3a, BNIP3L, Bok, bone sialoprotein, bonus, Boo, BPI, BRAL1, BRAG-1, BRAP, Bravo, BRCA1, BRN3a, BRN3b, BRN3c, brevican, BPR, BSAC, BUFFY, C1q, C1r, C1s, C2, C3, C4a, C4b, C5, C6, C7, C8a, C8b, C8g, C9, C1qBP, C3aR, C4BP<sub>a,b</sub>, C5R1, CR2, CIITA, C5L, c-E10, c-FLIP, c-Fms, c-Fos, c-IAP1, cIAP1, c-IAP-1, c-IAP2, cIAP2, c-IAP-2, c-Jun, c-Myc, c-Rel, cactus, CAD, cadherin, E, N, P, VE, calcineurin, CARD4,, CARD7, CARD9, CARD10, CARD11, CARD12, CARD14, CARDIAK, Carma1, CARMA-1, CARMA2, CARMA3, CARMA, CARMEN, CAP1, CAR1, CART1, CAS, CAS-L, caspase -1, -2, -3, 4, -5, -6, -7, -8, -9, -11, -12, -13, -14, Casper -1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, -21, -22, -23, -24, -25, -26, -

27, -28, CASH, CBL, CBL-B, CBL-C, CC-CKR-6, CCF, CCL, CCPI, CCRs, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD11, CD14, CD18, CD19, CD20, CD21 (CR2), CD22, CD23, CD25, CD27, CD27L, CD28, CD28LG1, CD28LG2, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD40, CD40L, CD41, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62E, L, H, CD66, CD63, CD64, CD66a-e, CD67, CD70, CD72, CD74, CD79a, b, CD80, CD84, CD85a-m, CD86, CD88, CD89, CD90, CD92, CD94, CD95, CD96, CD97, CD99, CD100, CD101, CD102, CD104, CD105, CD106, CD108, CD112, CD115, CD116, CD117, CD119, CD120a-b, CD121a-b, CD122, CD123, CD124, CD125, CD126, CD127, CD128a-b, CD130, CD131, CD132, CD134, CD135, CD136, CD137, CD140a, CD140b, CD143, CD144, CD146, CD147, CD148, CD150, CD151, CD152, CD153, CD154, CD155, CD158a-z, CD159, CD160, CD161, CD162, CD166, CD178, CD180, CD183, CD184, CD195, CD197, CD207, CD229, CD244, CDC2, CDC25, CDC42, CDK1, CDK2, CDK5, CDM, CEA, CEAL, CEACAM1, 6, C/EBP, CED1, CED2, CED3, CED4, CED5, CED6, CED7, CED8, CED9, Ced-9, CED10, CED11, CED12, CED, CEP-1, CES1, CES2, CES3, CETP, CeTRAF, Cezanne, CGR19, CGRP, Che1, Che-1, CHFR, chemokines, CHOP, CHUK, cIAP1, cIAP2, c-IAP1, c-IAP2, c-IAP-1, c-IAP-2, CIDE -A, CIDE-B, CIKS, CIN85, CIP-1, CIPER, CISK, Ckb-8, CKR1, 2, 3, 4, 5, CKRL1, Clan, CLAP, CLARP, CMD1, CMH1, CMKBR1, 2, 3, 4, 5, 6, CMPD1, conductin, Cop9 subunit 3, COP11, COPS3, COPS5, COT, COX-1, COX-2, CPAN, CPP32, CPZ, CRADD, CRAF1, CR8, CREB, CREM, Crk-II, crinkled, crmA, crmB, CSBP1, CSMF, CSN3, Csp-1, Csp-2, Csp-3, CSPG2, 3, Csx, CTACK, CTAP3, CTGF, CTLA4, cytochrome c, cytosolic PL A2, CXCLs, CXC-R3, DAAM1, Dad1, DAD-1, Damm, DAP1, DAP3, DAP5, DAP12, DAP kinase 1, DAPP1, DAXX, Dborg1, dCAD, DCCCK1, DCP1, Dcp-1, Dcp-2, DcR-1, DcR-2, DcR-3, DD2, Decay, DED, DEDAF, DEDD, DEDD2, dedpro1, defensin, DEFT, dFADD, DFF, DFF35, DFF40, DFF45, DG17, Diablo, DIAP1, DIAP2, Dickkopf, DIF, DIF2, DIHA, DIK, *Drosophila* IKK, PKC $\delta$ -interacting protein kinase, DIO1, DIP, disshevelled, diubiquitin, DKK1, 2, 3, 4, DLAK, DLK, DMDL, DNase II, Diva, DONG1, Dorsal, DP1, DP2, DP5, Drob1, DRP-1, DocA, dock188, Dok1, Doom, dorfin, DR3,4,5,6, DRAK 1-2, DREAM, DREP -1, -2, -3, -4, DrICE, DRONC, DRP1, DTR, DTS, DUSP, E1.1, E1B 19K, E10, E2Fs, E4BP4, E4ORF4, E8, E4, E48, E3RS, eae7, Ear7, EBAF, EBI1, EBP1, EBI6,

ECSIT, EDA, EDAR, Edradd, EFP, EGL1, Egr1-2-3, EHF, eIF-2aK, Eiger, ELAM, ELF2, ELK1-4, EMR1, ENA78, Endofin, Endoglin, Endophilin B1, endothelin, ENG, eNOS, eotaxin 1,2, ERN1, ERICE, ES18, Ets-1-2, ER81, ErbAa, ERG, ERM, ESE2, Eskine, ETV1, 2,3,4,5,6, exodus-1, exodus-2, exodus-3, FADD, Fas associated *via* death domain, FAF1, FAIM, FAN, FANCC, Fas, FAST, FAT10, fb1, FCAR, FELL, FEM-1, FEM-2, FHR1-2, FHR-3, FHR-4, FHR-5, FKBP, FIGF, FIL1d, e, eta, zeta, FIP2, FIP3, FKSG2, FIST, FKHL12, FKHR, FKHL1, FLAME-1, FLAME-3, FLAME3, FLASH, FLDED-1, FLI-1, FLI1, FLICE, FLICE2, FLICE-2, FLIP, FLT3L, Fliz1, Fln29, Fms, Fnk, fortilin, Fos, FOXO1A, FOXO3A, FOXE3, FPV039, Fra1, Fra2, Fractalkine, FRAP, FREAC8, Frizzled, Fzd, Fz, FRING, FRP1-2-3, FRP1(ATR), frpHE, FRZB-PEN, Fsp27, FUS, FUS6, Fusin, FXY, FY, G-coupled receptors, G10P1, G25K, G4R, G6C, G6E, GADD34, GADD45, GADD153, GATA1,2,3,4,5,6, GBP2, GCP2, GDFs, gelsolin, Gfi-1, Gfi1, GFRP1, GILZ, gingipain, GPCR, GL50, glycodelin A, GM2A, gp34, GPR5, GPR9, GPR-9-6, Granzyme B, Grim, GRMP, Groa, Grob, GRS, GSK $\beta$ , H2TF1, H731-like, Hakai, HB-EGF, Hck, HF1, HFB30, HFL3, HHARI, hIAP-1, hIAP1, Hid, HIF1  $\alpha$ , HIP1, HIP116, HIPPI, HIPK1,2,3, histamine receptors, HIVEP1,-3, HIV-EP1, HLTF, HM85, HM89, HM145, HMR, HNRPD, HRD1, Hrk, HtrA2, Huntingtin, HVEM, HVEML, HYP, IAP-1, IAP1, IAP2, IAP, iAPP, ICAD, ICBP90, ICE, ICEBERG, ICE-LAP3, ICE-LAP6, ICErel-II, ICErel-III, Ich1, ICH-1, Ich2, ICH-2, Ich3, ICH-3, ICOS, I-TRAF, I-FLICE, IEX-1m IFI, IFIT-1, IFIT-2, IFIT-3, IFIT-4, IFP35, IgE Fc receptor, IGF1 and its receptor, IGFBP-3, IKAP, Ikaros, IKB-1, Ikb-a, Ikb-b, Ikb-e, IKKAP1, IKK-1, IKK-2, IKK-a, IKK-b, IKKg, interleukins, interleukin receptors, IL1 antagonist, anti-IL1, IL1RacP, IL8R1, ILA, ILC, ILP, ILP-1, ILP-2, ILT1-11, ING1, ING2, ING3, Inhibin, INK4, INK4A, integrin, IP10, INP10, IP30, Ipaf, IRAK, IRAK2, IRAM-M, IRE1, RE1p, IRE, IRF, IRTA1-5, ISGF3g, ITA, It, Jab1, Jak1, 2, 3, JDP2, JIK, JN, K, K13, KARAP, KBF-1, KBF-2, KBF-3, KDS, KE05, KET, kf-1, KIAP, Killer, KIR2DL1-5, KIR2DS1-6, KROX2, L-Myc, lactalbumin  $\alpha$ , LAG1, LAIR1, LALBA, LAM, LAP1, LAP3, LAR, LARD, LARC, LATS1, 2, LBP, Lck, LCP2, LD78b, LEFTY, LESTR, Leu1, Leu8, Leu14, leukotactin, LFA3, LFG, LICE, LICE2, LIF, LIGHT, LIR1, LIR-2, LIR-3, LIR-4, LIR-5, LIR-6, LIR-7, LIR-8, Livin, LMP1, LMW5-HL, LOK, Lot1, LRDD, LRP, Low affinity NGFR, LTa, LTb, LTbR, LTP2, Ly63, lymphotactin, Ly1, Lyf1, Lysozyme, Lyt-10, LYVE1, LZK,

M11, M159L, M160L, MA-3, MACH, Mad, Mad3, MADD, Maf, c-Maf, makorin, MAL, MALT, MAP-1, MAPKKKKs, MAPKKKs, MAPKKs, MAPKs, Math1, Max, MBD4, MBLR, MBP1, MCL1, Mch2, Mch3, Mch4, Mch5, Mch6, MCP1, MCP2, MCP3, Mda-7, MD-1, MD-2, Mdm2, Mdm4, MdmX, MDP62, mE10, MEF2a, MEKKs, Mel-18, MEMD, Meprin, metacaspase, MIC1, MID1, MIF, MIG, MIHC, MIP1-2-2a-2b, MIP-T3, MIR, MIS, MITF, MKK6, MKL1, MKP1, ML-1, ML-IAP, MLN64, MLX, MMP-1, MMP-2, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MNDA, MNT, Mob1, mod (mdg4), MORT1, MPIF1, 2, MRFP, MRIT, Msx1, Msx2, MTAP44, Mtd, mTOR, MUC1, MUC2, MUL, MURF-1-2-3, myp-nop30, MxA, MxB, Mxi1, Mxi2, MYAK, Myc, MyD88, MyD118, MYLK, myoblast city, N-Myc, NAF1, NAIP, NALP1, NALP2, NAP2, NBAK3, Nbk, NBS1, NCA, NCAM, NCC-1, NCC-2, NCC-3, NCC-4, NDG1, neural sphingomyelinase, neuralin, NEMO, neogenin, neurotactin, neurocan, NF-kB, NF-X1, NFATs, NFIL3, NFIL6, NFkB1, 2, NIP1, NIP2, NIP3, NIPK, NIK, Nix, NKAT1-9, NKX2-5, nNOS, Notch, NOD-1, NOD-2, nop30, Nor-1, NOS2, NOS2B, NOS3, Nov, Noxa, NP10, Np95, Npc2, NPY3R, Nr-CAM, NR3, NR13, Nr-13, NRAGE, NRIF1, nucleolin, Nur77, NY-REN-64, OCIF, ODF, ODFR, OIAS, ORF16, osteoprotegerin, OSX, OX40, OX40L, OPG, OPGL, Osi, osteonectin, osteoponti, p14, p16, p33ING1, p35, p38, p49, p49, p55, p52, p53, p53AIP1, p53DINP1, p55, p60, p62, p62Dok, p63, p65, p73, p75NTR, p84, p100, p105, p193, p202, PAC1, PACAP, PACT, PAF400, PAG-3, PAG608, PAK1, PAK2, PAK3, PAP1, PAR4, paracaspase, PARC, Park2, parkin, PARP, PAX-2, PAX-3, PAX-5, PAX-8, PBEF, PBP, PD1, PDGF, PEA15, Pellino, PERK, PERP, PEK, Pelle, PEX10, PF4, PGRP, PI3K, Pidd, PIK-1, PLAB, Plk, Plk3, PKC, PKR, PKY, PLAGL1, PLAIDD, PLA2, PLC, PLD, Pli, Pml, PMP41, POSH, PP1A, PP14, PP2Ca, PRKR, PRSS25, polycystin 1, porimin, PRG1, Prk, PRL, prolactin receptor, PS-1, PS-2, PSCA, PSMD-11, PSMD-12, PSMD-13, PSP-C, PSK, PSSALRE, PTEN, PTK1, PTPs, PTP1C, PTP2C, PTP1G, PTPL1, PU.1, puckered, Pum, Q2/2, Rac, RAI, RANTES, RAX, Rb, Relish, RELT, Raf, RANK, RANKL, RAIDD, RBBP6, RBQ1, Rcm, Reaper, RelA, relaxin H1, H2, H3, RelB, Requiem, RFP, RFPL-1-2-3, RGS, RhoA, RICK, RIG-G, Ro52, Ro 60kDa, ROC-1, ROC-2, RORgamma, ROX, RIFF, RIP, RIP2, RIP3, RNM561, RNF, RP-8, RP8, RP105, Rpr, RRP5, RYBP, S9, S152, SAG, Salvador, SAP1, SAPK2A, Sara,

- 144 -


SARP 1,2,3, Sav, Sca2, SCA-2, SCC-S2, SCF, SCDGF, SCM1-1a, Scythe, SDF1, selectin L-E-P, SENP1, SENP2, sentrin/SUMO-specific protease, SETA, SFRP1-2-3-4-5, SFTP2, SFTPC, SGK, SGL, SGN5, SH2D1A, SHP1, 2, Siah, SIMPL, SIP27, SIP18, SIR2, SIVA, SLC, SLK, SLP-65, SLP-76, SLUG, Smac, SMADs, SMARCA3, SMN, SMT 3A, B, 3C, SNAIL, SNF2L3, SODD, somatostatin, Son3, SOX9, SP5, SP-C, SPARC, sphigomyelinase, Smase, SPOP, SPP1, SPRK, Spatzle, SFRP1,2,5, SS-56, SSA, SSA1, SSA2, ST2L, stabilin 1-2, STATs, STCP1, STG6, STEP, STM-2, Stra3, STRICA, Substance P, SUMO1, survivin, SYK, SY, T cell receptor, T2BP, T6BP, TAB1, Tab2, Tabby, TACI, TACTILE, Tag7, tachykinin, TAJ, TAK1, Tak1, TALL-1, TANK, TAO1, TAO2, TARC, TBX1, TBX-2, TBX-3, TBX-4, TBX-10, TBX-18, TBX-19, TBX-20, TBX-21, TBX-22, TCA3, TCA-3, TC1, TC2, TCR, TCTP, TDAG51, TEAP, TECK, TEGT, TEL, (TEL1), TEL2 (TELb), telokin, TERF, TFT, TGb, TGF $\beta$ -1, TGF $\beta$ -2, TGF $\beta$ -3, THG1, THRa, Thy-1, TIA1, TIAP, TIEG, TIF1, TIF $\gamma$ , TIL6, TIMP1-2-3, TIP49, Tip60, TIRAP, TIS, TLRs, TLS, TMS1, TNFa, TNFAIP3, A20, TNFAIP6, TNFb, TNF-C, TNFR1, TNFR2, TNFR-II, TNFRSF1-19, Toll, Tollo, Tollip, TONEBP, Toso, Tp44, TPL-2, TR3, TR2L, TRABID, TRADD, TRADE, TRAF1, TRAF1(Dm), TRAF2, TRAF2(Dm), TRAF3, TRAF4, TRAF5, TRAF6, TRAF6(Dm), TRAFamn, TRAIL, TRAIL-R2, TRAMP, TRANCE, TRC8, TRIAD1-3, TRIF, TRIM, TRIP15, TRF-1, TRF-2, TRF1, TRF2, traube, TRDL-1, TRG, TRH, TRICK2, TRIP, Tristetraproline, TROY, TRRAP, TSC-22, TSC-22R, TTRAP, Tube, TUCAN, TWEAK, TX, TXBP151, TY, Tyk, UBCH7BP, UL36, UL37, Ulp, Unc5, UNC5h3, Urinary, stone protein (SPP1), USP7, usurpin, uterophi, vasopressin, vav, vav1, vav2, vav3, vav-1, vav-2, vav-3, versican, vICA, VIAF1, vBcl-2, VEG1, VEGF, Ventroptin, VG-1, VG71, VHR, v-IAPs, VI, warts, Wengen, WIG1, WISP-1, 2, 3, Wnt, WSL-1, WT1, WW45, WWOX, XAF1, XAP4, XCL1, 2, XEDAR, XIAP1, xRI, xRII, XICE, XICEa, XICE, Yama, YopJ, YY1AF, Zac, Zac1, ZAP70, ZBP89, zf3, ZFP26, ZFP127, ZH-DR, ZNF-40, ZNF-124, ZNF-148, as TFs, ZNF-144, ZNF-147, ZNF-179, ZNF-313, ZNF-364 as RING, ZIP-kinase, ZPR, 18 wheeler, 24.6K Glu/Pro-rich, 4-1BB, 4-1BBL, 4-1BB ligand and 53BP2, 7TM.

11. The methods of Claim 1 or 4 or 5 or 6 wherein the pro-survival protein is selected from Bcl-2, Bcl-XL, Mcl-1 and A1.




- 145 -


12. The method of Claim 1 or 4 or 5 or 6 wherein the compound is selected from




18:3n-3




22:6n-3




20:4n-6









23:4n-6















20:5n-3




15-OOH-20:4n-6

 $\beta$ -oxa-23:4n-6 (MP3) $\beta$ -oxa-21:4n-3 (MP7) $\beta$ -oxa-21:3n-6 (MP4)16-OH- $\beta$ -oxa-21:3n-6 (TR1) $\beta$ -oxa-21:3n-3 (MP5)16-OH- $\beta$ -oxa-21:3n-3 (TR2) $\beta$ -oxa-25:6n-3 (MP6)


- 146 -

 $\beta$ -thia-21:0 (MP2) $\beta$ -thia-25:6n-3 (MP14) $\beta$ -thia-21:3n-6 (MP9) $\beta$ -thia-23:4n-6 (MP8) $\beta$ -thia-21:3n-3 (MP10) $\alpha$ -carboxymethyl-  $\beta$ -thia-23:4n-6 (MP15) $\gamma$ -thia-22:3 (n-6) $\gamma$ -thia-24:4 (n-6) $\gamma$ -thia-22:3 (n-3) $\gamma$ -thia-25:6 (n-3)15-OOC(CH<sub>3</sub>)<sub>2</sub>OCH<sub>3</sub>-20:4n-6 (MP16)15-OOC(CH<sub>3</sub>)<sub>2</sub>OCH<sub>3</sub>- $\beta$ -oxa 23:4n-6 (MP17)


- 147 -




20:4n-6 Gly (PT1)




20:4n-6 Asp (PT2)




20:5n-3 Gly (PT3)




20:5n-3 Asp (PT4)




22:6n-3 Gly (PT5)




22:6n-3 Asp (PT6)




18:3n-6 Gly (PT7)



18:3n-6 Asp (PT8)











18:3n-3 Gly (PT9)



18:3n-3 Asp (PT10)

- 148 -

19:0-NO<sub>2</sub> (Lx1)21:0γ-NO<sub>2</sub> (Lx6)19:3 (n-3)-NO<sub>2</sub> (Lx2)23:4 (n-6) γ-NO<sub>2</sub> (Lx7)19:3 (n-6)-NO<sub>2</sub> (Lx3)γ,γ(COOH), 19:0-NO<sub>2</sub> (Lx8)21:4 (n-6)-NO<sub>2</sub> (Lx4)γ,γ(COOH), 21:4 (n-6)-NO<sub>2</sub> (Lx9)23:6 (n-3)-NO<sub>2</sub> (Lx5)

13. The method of Claim 1 wherein the treatment is for pain including *inter alia* neuropathic or neurological pain, chronic pain, acute pain, migraine, headache inflammatory pain, postoperative pain, pain due to multiple sclerosis, Parkinson's disease or other neurological or autoimmune disorder or following or during periods of anxiety, delayed onset muscle soreness, burns or during or following infection or a convulsion, post-poliomyelitic pain, bipolar disorder, panic attack or epilepsy.

14. The method of Claim 1 wherein the treatment is for depression, including major depression (single episode, recurrent, melancholic), atypical, dysthymia, subsyndromal, agitated, retarded, co-morbid with cancer, diabetes, or post-myocardial infarction, involutional, bipolar disorder, psychotic depression, endogenous and reactive, obsessive-compulsive disorder, or bulimia. In addition, NAALADase inhibitors can be used to treat patients suffering from pain (given alone or in combination with morphine, codeine, or

- 149 -

dextropropoxyphene), obsessive-compulsive personality disorder, post-traumatic stress disorder, hypertension, atherosclerosis, anxiety, anorexia nervosa, panic, social phobia, stuttering, sleep disorders, chronic fatigue, cognition deficit associated with Alzheimer's disease, alcohol abuse, appetite disorders, weight loss, agoraphobia, improving memory, amnesia, smoking cessation, nicotine withdrawal syndrome symptoms, disturbances of mood and/or appetite associated with pre-menstrual syndrome, depressed mood and/or carbohydrate craving associated with pre-menstrual syndrome, disturbances of mood, disturbances of appetite or disturbances which contribute to recidivism associated with nicotine withdrawal, circadian rhythm disorder, borderline personality disorder, hypochondriasis, pre-menstrual syndrome (PMS), late luteal phase dysphoric disorder, pre-menstrual dysphoric disorder, trichotillomania, symptoms following discontinuation of other antidepressants, aggressive/intermittent explosive disorder, compulsive gambling, compulsive spending, compulsive sex, psychoactive substance use disorder, sexual disorder, schizophrenia, premature ejaculation, or psychiatric symptoms selected from stress, worry, anger, rejection sensitivity and lack of mental or physical energy.

15. The method of Claim 1 wherein the treatment is for Moderate Mental Retardation, Severe Mental Retardation, Profound Mental Retardation, Unspecified Mental Retardation, Autistic Disorder, Pervasive Development Disorder NOS, Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Group Type, Conduct Disorder, Solitary Aggressive Type, Conduct Disorder, Undifferentiated Type, Tourettes Disorder, Chronic Motor or Vocal Tic Disorder, Transient Tic Disorder, Tic Disorder NOS, Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, Uncomplicated, Primary Degenerative Dementia of The Alzheimer Type, Senile Onset, with Delirium, Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions, Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression, Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, Uncomplicated, Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delirium, Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delusions, Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression, Multi-infarct dementia, Uncomplicated, Multi-infarct dementia, with Delirium, Multi-infarct Dementia, with

- 150 -

Delusions, Multi-infarct Dementia, with Depression, Senile Dementia NOS, Presenile Dementia NOS, Alcohol Withdrawal Delirium, Alcohol Hallucinoses, Alcohol Dementia Associated with Alcoholism, Amphetamine or Similarly Acting Sympathomimetic Intoxication, Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder, Cannabis Delusional Disorder, Cocaine Intoxication, Cocaine Delirium, Cocaine Delusional Disorder, Hallucinogen Hallucinoses, Hallucinogen Delusional Disorder, Hallucinogen Mood Disorder, Hallucinogen Posthallucinogen Perception Disorder, Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Intoxication, Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delirium, Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delusional Disorder, Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Mood Disorder, Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Organic Mental Disorder NOS, Other or unspecified Psychoactive Substance Intoxication, Other or Unspecified Psychoactive Substance Delirium, Other or Unspecified Psychoactive Substance Dementia, Other or Unspecified Psychoactive Substance Delusional Disorder, Other or Unspecified Psychoactive Substance Hallucinoses, Other or Unspecified Psychoactive Substance Mood Disorder, Other or Unspecified Psychoactive Substance Anxiety Disorder, Other or Unspecified Psychoactive Substance Personality Disorder, Other or Unspecified Psychoactive Substance Organic Mental Disorder NOS, Delirium, Dementia, Organic Delusional Disorder, Organic Hallucinoses, Organic Mood Disorder, Organic Anxiety Disorder, Organic Personality Disorder, Organic Mental Disorder, Obsessive Compulsive Disorder, Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder NOS, Body Dysmorphic Disorder, Hypochondriasis (or Hypochondriacal Neurosis), Somatization Disorder, Undifferentiated Somatoform Disorder, Somatoform Disorder NOS, Intermittent Explosive Disorder, Kleptomania, Pathological Gambling, Pyromania, Trichotillomania and Impulse Control Disorder NOS.

16. The method of Claim 1 wherein the treatment is for Schizophrenia, Catatonic, Sub-chronic, Schizophrenia, Catatonic, Chronic, Schizophrenia, Catatonic, Sub-chronic with Acute Exacerbation, Schizophrenia, Catatonic, Chronic with Acute Exacerbation, Schizophrenia, Catatonic, in Remission, Schizophrenia, Catatonic, Unspecified,

- 151 -


Schizophrenia, Disorganized, Chronic, Schizophrenia, Disorganized, Subchronic with Acute Exacerbation, Schizophrenia, Disorganized, Chronic with Acute Exacerbation, Schizophrenia, Disorganized, in Remission, Schizophrenia, Disorganized, Unspecified, Schizophrenia, Paranoid, Subchronic, Schizophrenia, Paranoid, Chronic, Schizophrenia, Paranoid, Sub-chronic with Acute Exacerbation, Schizophrenia, Paranoid, Chronic with Acute Exacerbation, Schizophrenia, Paranoid, in Remission, Schizophrenia, Paranoid, Unspecified, Schizophrenia, Undifferentiated, Sub-chronic, Schizophrenia, Undifferentiated, Chronic, Schizophrenia, Undifferentiated, Sub-chronic with Acute Exacerbation, Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation, Schizophrenia, Undifferentiated, in Remission, Schizophrenia, Undifferentiated, Unspecified, Schizophrenia, Residual, Sub-chronic, Schizophrenia, Residual, Chronic, Schizophrenia, Residual, Subchronic with Acute Exacerbation, Schizophrenia, Residual, Chronic with Acute Exacerbation, Schizophrenia, Residual, in Remission, Schizophrenia, Residual, unspecified, Delusional (Paranoid) Disorder, Brief Reactive Psychosis, Schizophreniform Disorder, Schizoaffective Disorder, induced Psychotic Disorder, Psychotic Disorder NOS (Atypical Psychosis), Bipolar Disorder, Mixed, Severe, without Psychotic Features, Bipolar Disorder, Manic, Severe, without Psychotic Features, Bipolar Disorder, Depressed, Severe, without Psychotic Features, Bipolar Disorder, Mixed, with Psychotic Features, Bipolar Disorder, Manic, with Psychotic Features, Bipolar Disorder, Depressed, with Psychotic Features, Bipolar Disorder NOS, Major Depression, Single Episode, with Psychotic Features, Major Depression, Recurrent with Psychotic Features Personality Disorders, Paranoid Personality Disorders, Schizoid, Personality Disorders, Schizotypal, Personality Disorders, Anti-social, Personality Disorders and Borderline.

17. The method of Claim 1 wherein the treatment is for Anxiety Disorders, Panic Disorder, Panic Disorder with Agoraphobia, Panic Disorder without Agoraphobia, Agoraphobia without History of Panic Disorders, Social Phobia, Simple Phobia, Organic Anxiety Disorder, Psychoactive Substance Anxiety Disorder, Separation Anxiety Disorder, Avoidant Disorder of Childhood or Adolescence, and Overanxious Disorder.

- 152 -

18. The method of Claim 1 wherein the treatment is for cardiovascular disease includes strokes and any condition of the systemic vasculature and includes atherosclerosis, chronic heart failure and general heart disease.

19. A compound of general Formula (I)



wherein

$R_1$  is a saturated or unsaturated hydrocarbon chain of from about 9 to about 26 carbon atoms and which is optionally carries one or more of a oxa, thia, hydroxy, hydroperoxy, epoxy and peroxy substitution;

$R_2$ ,  $R_4$  and  $R_6$  may be the same or different and each is selected from  $O_2$ ,  $NO$ ,  $NO_2$ ,

$S(O)_x$ ,  $C(H)_y$ ,  $H$ ,  $COOH$ ,  $P(X)_\delta(Y)$ ,  $N(H)_z$ ,  $C=O$ ,  $OH$ ,  $\text{---}\overset{\overset{O}{\parallel}}{C}\text{---}NH\text{---}$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino, mono-acid di- $C_{1-6}$  alkylamino,  $C_{1-6}$  alkylthio,  $S(O)_x\text{---}C_{1-3}$  alkyl,  $C_{1-6}$  alkoxycarbonyl, halo selected from fluoro, chloro, bromo and iodo, oxo, amidino and guanidino,  $C_{2-12}$  alkenyl,  $C_{2-12}$  alkynyl, aryl, heteroaryl and cyano, wherein  $x$  and  $z$  are 0, 1 or 2 and  $y$  is 0, 1, 2 or 3 and  $X$  is  $O$ ,  $S$  or  $NR_8$ ,  $Y$  is  $OR_9$ ,  $SR_{10}$  or  $NR_{11}R_{12}$  and  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  are selected from  $H$ , alkyl, alkenyl, alkynyl, aryl and heteroaryl,  $\delta$  is 0 or 1;

each of  $R_3$ ,  $R_5$  and  $R_7$  is respectively  $[(CH_2)_j (COOH)_k]_l$ ,  $[(CH_2)_m (COOH)_n]_o$  and  $[(CH_2)_p (COOH)_q]_r$ , wherein each of  $j$ ,  $m$  and  $p$  is 0, 1, 2, 3, 4, 5 or 6, each of  $k$ ,  $n$  and  $q$  is 0, 1 or 2, and each of  $l$ ,  $o$  and  $r$  is 0 or 1,



- 153 -

each of c, i and f is 0 or 1 or 2;

each of a, d and g is 0 or 1 or 2; and

each of b, e and h is 0 or 1 or 2.